Ionis Says Eplontersen Got Fast Track Status To Treat Transthyretin-mediated Amyloid Cardiomyopathy

(RTTNews) - Ionis Pharmaceuticals, Inc. (IONS) Thursday said Fast Track designation has been granted by the Food and Drug Administration (FDA) to Ionis and AstraZeneca's eplontersen, an investigational therapy for the treatment of transthyretin-mediated amyloid cardiomyopathy (AT https://www.nasdaq.com/articles/ionis-says-eplontersen-got-fast-track-status-to-treat-transthyretin-mediated-amyloid